Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE3

מצבים רפואיים

Non-Small-Cell Lung Cancer · Metastatic Non-Small-Cell Lung Cancer · Advanced Non-Small-Cell Lung Cancer · EGFR P-Loop and Alpha C-Helix Compressing · EGFR PACC · EGFR Uncommon Mutations

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

  • University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

  • UCSF Medical Center-Mission Bay, San Francisco, California, United States

  • Kaiser Permanente Medical Center, Vallejo, California, United States

  • University of Colorado Health, Aurora, Colorado, United States

  • Illinois Cancer Specialists, Arlington Heights, Illinois, United States

  • University of Illinois Hospital and Health Sciences Systems, Chicago, Illinois, United States

  • Northwell Health/R.J. Zuckerberg Cancer Center, Lake Success, New York, United States

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States

  • Ohio State University Hospitals, Columbus, Ohio, United States

  • Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

  • Texas Oncology, Dallas, Texas, United States

  • The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • University of Virginia, Charlottesville, Virginia, United States

  • Virginia Cancer Specialists, Fairfax, Virginia, United States

  • Shenandoah Oncology, P.C., Winchester, Virginia, United States

  • Swedish Cancer Institute, Edmonds, Washington, United States

  • Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia

  • Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia

  • GenesisCare North Shore Health Hub, St Leonards, New South Wales, Australia

  • Austin Health, Heidelberg, Victoria, Australia

  • Alberta Health Services, Tom Baker Cancer Centre, Calgary, Alberta, Canada

  • BC Cancer Vancouver Centre, Vancouver, British Columbia, Canada

  • The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada

  • Sunnybrook Research Institute, Toronto, Ontario, Canada

  • Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada

  • Hospices Civil de Lyon, Bron, Auvergne-Rhône-Alpes, France

  • Hospital Nord de Marseille, Marseille, Bouches-du-Rhone, France

  • Centre Francois Baclesse, Caen, Calvados, France

  • Hopital Larrey, Toulouse, Occitanie, France

  • Centre Leon-Berard, Lyon, France

  • Hopital Nord Guilaume-et-Rene-Laennec CHU de Nantes, Saint-Herblain, France

  • Insitut de Canderologie d I'Ouest, Saint-Herblain, France

  • Henry Dunant Hospital Center, Athens, Greece

  • University General Hospital Attikon - General Hospital of West Attica H AGIA VARVARA, Athens, Greece

  • Athens Medical Center S.A., European Interbalkan Medical Center, Thessaloniki, Greece

  • Thoracic General Hospital of Athens I Sotiria, Thessaloniki, Greece

  • Queen Mary Hospital, Hong Kong, Hong Kong, Hong Kong

  • Humanity and Health Clinical Trial Centre, Central, Hong Kong

  • SOC Oncologia Medica e dei Tumori Immuno-correlati, Aviano, Italy

  • Istituto Europeo di Oncologia (IEO), Milan, Italy

  • Aichi Cancer Center, Nagoya, Aichi-ken, Japan

  • Kurume University Hospital, Kurume-Shi, Fukuoka, Japan

  • National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan

  • Hyogo Cancer Center, Akashi-shi, Hyōgo, Japan

  • Miyagi Cancer Center, Natori-shi, Miyagi, Japan

  • Niigata Cancer Center Hospital, Niigata, Niigata, Japan

  • Kansai Medical University Hospital, Hirakata-shi, Osaka, Japan

  • Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan

  • Tokyo Metropolitan Komagome Hospital, Bunkyō-Ku, Tokyo, Japan

  • National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

  • OncoCar Cancer Centre, Petaling Jaya, Selangor, Malaysia

  • Hospital Kuala Lumpur, Kuala Lumpur, WP Kuala Lumpur, Malaysia

  • National Cancer Centre Singapore, Singapore, Singapore

  • Curie Oncology (Farrer), Singapore, Singapore

  • Tan Tok Seng Hospital, Singapore, Singapore

  • The Catholic University of Korea, St. Vincent's Hospital, Suwon, Gyeonggi-do, South Korea

  • Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, South Korea

  • Gachon University Gil Medical Center, Incheon, South Korea

  • Kyung Hee University Hospital, Seoul, South Korea

  • Kangbuk Samsung Hospital, Seoul, South Korea

  • Asan Medical Center, Seoul, South Korea

  • Samsung Medical Center, Seoul, South Korea

  • Hospital Universitari Son Espases, Palma, Balearic Islands, Spain

  • Hospital Clinic de Barcelona, Barcelona, Spain

  • Hospital QuironSalud Malaga, Málaga, Spain

  • Hospital Universitario Central de Asturias, Oviedo, Spain

  • Hospital Universitario y Politecnico La Fe, Valencia, Spain

  • Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan

  • Taichung Veterans General Hospital, Taichung, Taiwan

  • National Taiwan University Cancer Center, Taipei, Taiwan

  • Taipei Veterans General Hospital, Taipei, Taiwan

  • Mahidol University - Siriraj Hospital, Bangkoknoi, Bangkok, Thailand

  • Chulabhorn Hospital, Lak Si, Bangkok, Thailand

  • Prince of Songkla Hospital, Hat Yai, Changwat Songkhla, Thailand

  • University College London Hospitals NHS Foundation Trust, London, England, United Kingdom

  • The Christie NHS Foundation Trust, Manchester, England, United Kingdom

  • The Royal Marsden NHS Foundation Trust, London, United Kingdom

מובילי המחקר
  • Morgan Lam

    Study Director

    ArriVent BioPharm